Key Quantitative Figures

  • Total of 8 promoter group members seeking reclassification
  • Combined shareholding: 949,988 equity shares
  • Combined percentage: 0.93% of total share capital
  • Individual shareholdings:
  • Madhurika Narendra Shah: 12,000 shares (0.01%)
  • Hemant Babubhai Choksi: 24,000 shares (0.02%)
  • Mukesh Kantilal Shah: 14,400 shares (0.01%)
  • Aruna Navnit Shah: 5,040 shares (0.01%)
  • Vikram Kirtilal Shah: 200 shares (0.00%)
  • Kiran Piyush Shah: 15,388 shares (0.02%)
  • Kinjal Siddharth Jhaveri: 816,160 shares (0.81%)
  • Nina Vijay Shah: 60,000 shares (0.06%)
  • Neela Pradeep Shah: 2,800 shares (0.00%)

Dates of Action

  • Request received from shareholders: 19th May, 2026
  • Board meeting date: 20th May, 2026 (commenced at 02:00 PM, concluded at 09:10 PM)
  • Resolution date: 20th May, 2026
  • Filing date with exchanges: 22nd May, 2026

Parties Involved

  • Anuh Pharma Limited (Company)
  • BSE Limited and National Stock Exchange of India Limited (Stock Exchanges)
  • 8 promoter group members seeking reclassification
  • Board of Directors of Anuh Pharma Limited
  • Authorized signatories: Mr. Bipin Shah (Vice Chairman), Mr. Ritesh B. Shah (Joint Managing Director), Mr. Vivek Shah (Joint Managing Director), Mr. Bharat Shah (Director), Mr. Ketan Shah (Director), Mr. Manan Vadhan (Company Secretary & Compliance Officer)

Conditions Met for Reclassification

The Board confirmed that the affected persons:

  • Are neither involved in management nor day-to-day affairs of the Company
  • Do not exercise any control over company affairs, directly or indirectly
  • Do not have any special rights through formal or informal arrangements including shareholder agreements
  • Are not represented on the Board of Directors
  • Do not act as key managerial personnel
  • Are not "wilful defaulters" as per RBI Guidelines
  • Are not fugitive economic offenders

Approval Requirements

  • Board approval obtained on 20th May, 2026 (unanimous resolution)
  • Subject to approval of members of the Company (if required)
  • Subject to approval of Stock Exchanges where equity shares are listed
  • Subject to other approvals as may be necessary

Additional Information

  • Meeting held at registered office: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai-400018, Maharashtra
  • Meeting also conducted through video conferencing
  • Certified true copy of resolution attached to filing
  • Information available on company website: www.anuhpharma.com

Financial Impact

Reclassification affects 0.93% of total share capital from promoter group to public category. No immediate financial impact disclosed.

Capital Structure Impact

Change in promoter group holding reduction by 0.93%, with corresponding increase in public shareholding. No dilution or change in total outstanding shares.